Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rollover trial tests continued sitravatinib combo for advanced cancers

NCT ID NCT04887870

Disease control Sponsor: Mirati Therapeutics Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This study looked at the safety and effectiveness of continuing sitravatinib, a targeted cancer drug, either alone or combined with other therapies like nivolumab or pembrolizumab, in people with advanced or metastatic solid tumors. It enrolled 52 patients who were already benefiting from sitravatinib in a previous study. The main goal was to track side effects and how long the cancer stayed under control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sitravatinib (a targeted therapy) alone or combined with other anticancer drugs like nivolumab or pembrolizumab
What this could lead to
If successful, this could show that continuing sitravatinib-based treatment is safe and may help control advanced cancers for longer.
What could go wrong
This is a small rollover study (52 people) that only included patients already benefiting from treatment. Results may not apply to all patients, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

49 people

The number who actually took part.

Started

Jun 2021

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Currently receiving sitravatinib single- agent or in combination with other therapeutic agent(s) in another Mirati- sponsored protocol * Currently tolerating the treatment regimen in the parent protocol * Experiencing clinical benefit with or without prior radiographic progression from the treatment regimen in the parent protocol in the opinion of the investigator and the investigator determines that continuing treatment is in the patient's best interest Exclusion Criteria: * Known or suspected presence of other cancer * Other life- threatening illness or organ system dysfunction compromising safety evaluation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced or metastatic solid malignancies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced or metastatic solid malignancies

Contacts and locations

Locations

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Local Institution - 516-014-001

    Austin, Texas, 78758, United States

  • Local Institution - 516-014-002

    Boston, Massachusetts, 02215, United States

  • Local Institution - 516-014-004

    Columbus, Ohio, 43210, United States

  • Local Institution - 516-014-005

    Minneapolis, Minnesota, 55455, United States

  • Local Institution - 516-014-011

    Albany, New York, 12208, United States

  • Local Institution - 516-014-013

    Houston, Texas, 77030, United States

  • Local Institution - 516-014-029

    Goshen, Indiana, 46526, United States

  • Memorial Sloan Kettering Cancer Center - Arnold and Marie Schwartz Cancer Research Building

    New York, New York, 10065, United States

  • NEXT Virginia

    Fairfax, Virginia, 22031, United States

  • Rocky Mountain Cancer Centers - Littleton

    Littleton, Colorado, 80218, United States

  • USOR - Texas Oncology Northeast Texas - Denison

    Denison, Texas, 75020, United States

  • Urology Cancer Center and GU Research Network

    Omaha, Nebraska, 68130, United States